Pacific Biosciences Of California (PACB) Operating Expenses (2010 - 2026)

Pacific Biosciences Of California's Operating Expenses history runs 17 years deep, the most recent figure standing at $21.2 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 95.04% year-over-year to $21.2 million in Q1 2026; TTM through Mar 2026 was $193.3 million, a 77.17% decrease from a year earlier, with the FY2025 full-year figure at $599.6 million, up 17.21% from the prior year.
• Operating Expenses retreated to $21.2 million in Q1 2026 per PACB's latest filing, from $57.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $427.6 million in Q1 2025 and bottomed at $21.2 million in Q1 2026.
• The 5-year median for Operating Expenses is $91.7 million (2022), against an average of $110.3 million.
• Across the five-year window, Operating Expenses soared 634.72% in 2022 and slumped 95.04% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $92.2 million in 2022, then advanced by 5.31% to $97.1 million in 2023, then jumped by 67.92% to $163.1 million in 2024, then sank by 64.58% to $57.8 million in 2025, then tumbled by 63.3% to $21.2 million in 2026.
• Per Business Quant, the three latest PACB Operating Expenses figures stand at $21.2 million (Q1 2026), $57.8 million (Q4 2025), and $54.8 million (Q3 2025).